302 related articles for article (PubMed ID: 29173147)
1. Recent Developments of 18F-FET PET in Neuro-oncology.
Muoio B; Giovanella L; Treglia G
Curr Med Chem; 2018; 25(26):3061-3073. PubMed ID: 29173147
[TBL] [Abstract][Full Text] [Related]
2. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[
Langen KJ; Stoffels G; Filss C; Heinzel A; Stegmayr C; Lohmann P; Willuweit A; Neumaier B; Mottaghy FM; Galldiks N
Methods; 2017 Nov; 130():124-134. PubMed ID: 28552264
[TBL] [Abstract][Full Text] [Related]
3. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
5. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
Pauleit D; Floeth F; Hamacher K; Riemenschneider MJ; Reifenberger G; Müller HW; Zilles K; Coenen HH; Langen KJ
Brain; 2005 Mar; 128(Pt 3):678-87. PubMed ID: 15689365
[TBL] [Abstract][Full Text] [Related]
6. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
[TBL] [Abstract][Full Text] [Related]
7. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
9. O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results.
Stegmayr C; Willuweit A; Lohmann P; Langen KJ
Curr Radiopharm; 2019; 12(3):201-210. PubMed ID: 30636621
[TBL] [Abstract][Full Text] [Related]
10. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.
Weckesser M; Langen KJ; Rickert CH; Kloska S; Straeter R; Hamacher K; Kurlemann G; Wassmann H; Coenen HH; Schober O
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):422-9. PubMed ID: 15650870
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
[TBL] [Abstract][Full Text] [Related]
12. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
13. [Improved diagnostics of cerebral gliomas using FET PET].
Langen KJ; Floeth FW; Stoffels G; Hamacher K; Coenen HH; Pauleit D
Z Med Phys; 2007; 17(4):237-41. PubMed ID: 18254545
[TBL] [Abstract][Full Text] [Related]
14. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
15. Can Early Postoperative O-(2-
Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
[TBL] [Abstract][Full Text] [Related]
16. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
[TBL] [Abstract][Full Text] [Related]
17. Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience.
Evangelista L; Cuppari L; Bellu L; Bertin D; Caccese M; Reccia P; Zagonel V; Lombardi G
Curr Radiopharm; 2019; 12(3):220-228. PubMed ID: 30644351
[TBL] [Abstract][Full Text] [Related]
18. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
20. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
